Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label active-controlled study of AK2017 injection in pediatric short stature
CTR20234263Phase 2Active
- Sponsor
- Anke Bio
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of AK2017 in growth hormone deficiency (GHD), Idiopathic Short Stature (ISS), sponsored by Anke Bio. Started May 2024; status: active.
02
Drugs
AK2017
03
Conditions
growth hormone deficiency (GHD)Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on CTR20234263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234263.